Association of Common C-Reactive Protein (CRP) Gene Polymorphisms With Baseline Plasma CRP Levels and Fenofibrate Response
- 1 May 2008
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 31 (5), 910-915
- https://doi.org/10.2337/dc07-1687
Abstract
OBJECTIVE—C-reactive protein (CRP) is an inflammatory marker that contributes to the prediction of cardiovascular disease. We investigated the influences of CRP polymorphisms on baseline CRP levels and fenofibrate-induced CRP changes in subjects with the metabolic syndrome. RESEARCH DESIGN AND METHODS—We examined the association of CRP single nucleotide polymorphisms (SNPs) (m772A>G, m301G>A >T, i178T>A, 3u1273C>T, and 3u2131C>T) with baseline plasma CRP levels among 1,123 white U.S. participants in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study and the modulating effect of these SNPs on CRP response to a 3-week fenofibrate treatment among 290 participants with the metabolic syndrome. RESULTS—There were strong associations of m301G>A>T (rs3091244; P = 0.003), i178T>A (rs1417938; P = 0.001), 3u1273C>T (rs1130864; P = 0.001), and 3u2131C>T (rs1205; P < 0.001) with baseline CRP levels. Moreover, among subjects with the metabolic syndrome, fenofibrate induced the greatest reduction in CRP levels for TT subjects of the i178T>A compared with TA and AA subjects (−30 for TT, −19 for TA, and −11% for AA; P = 0.004). Similarly, for the m301G>A>T, major allele carriers displayed maximal reduction of CRP over noncarriers (−20 for GG, −15 for GA and GT, and −0.3% for TA and AA; P = 0.020). CONCLUSIONS—Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. This knowledge could contribute to a better prediction of therapeutic success.Keywords
This publication has 20 references indexed in Scilit:
- Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic SyndromeDiabetes Care, 2007
- The −256T>C Polymorphism in the Apolipoprotein A-II Gene Promoter Is Associated with Body Mass Index and Food Intake in the Genetics of Lipid Lowering Drugs and Diet Network StudyClinical Chemistry, 2007
- Association of Common CRP Gene Variants with CRP Levels and Cardiovascular EventsAnnals of Human Genetics, 2005
- C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulusAtherosclerosis, 2005
- The metabolic syndrome, inflammation and cardiovascular disease in type 2 diabetesCurrent Opinion in Lipidology, 2004
- Human CRP Gene Polymorphism Influences CRP LevelsArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Gemfibrozil Reduces Plasma C-Reactive Protein Levels in Abdominally Obese Men With the Atherogenic Dyslipidemia of the Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Fibrates down-regulate IL-1–stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB–C/EBP-β complex formationBlood, 2003
- Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.Published by Rockefeller University Press ,2002
- Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1Nature Genetics, 2002